Bausch + Lomb Corp
BLCO15.190USD
-0.190-1.24%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
5.37BMarket Cap
LossP/E TTM
More Details of Bausch + Lomb Corp Company
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Company Info
Ticker SymbolBLCO
Company nameBausch + Lomb Corp
IPO dateMay 06, 2022
CEOMr. Brenton L. (Brent) Saunders, J.D.
Number of employees13500
Security typeOrdinary Share
Fiscal year-endMay 06
Address520 Applewood Crescent
CityVAUGHAN
Stock exchangeNYSE Consolidated
CountryCanada
Postal codeL4K 4B4
Phone19082552864
Websitehttps://ir.bausch.com/
Ticker SymbolBLCO
IPO dateMay 06, 2022
CEOMr. Brenton L. (Brent) Saunders, J.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Mr. Andrew J. Stewart
Mr. Andrew J. Stewart
President - Global Pharmaceuticals and International Consumer
President - Global Pharmaceuticals and International Consumer
--
--
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Devices
448.00M
39.40%
OTC
409.00M
35.97%
Pharmaceuticals
222.00M
19.53%
Branded and other Generics
54.00M
4.75%
Other revenues
4.00M
0.35%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Devices
448.00M
39.40%
OTC
409.00M
35.97%
Pharmaceuticals
222.00M
19.53%
Branded and other Generics
54.00M
4.75%
Other revenues
4.00M
0.35%
Shareholding Stats
Updated: Mon, Aug 18
Updated: Mon, Aug 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bausch Health Companies Inc
87.69%
Icahn Associates Corporation
0.99%
Deutsche Bank Securities Inc.
0.96%
Alberta Investment Management Corporation
0.92%
D. E. Shaw & Co., L.P.
0.74%
Other
8.70%
Shareholders
Shareholders
Proportion
Bausch Health Companies Inc
87.69%
Icahn Associates Corporation
0.99%
Deutsche Bank Securities Inc.
0.96%
Alberta Investment Management Corporation
0.92%
D. E. Shaw & Co., L.P.
0.74%
Other
8.70%
Shareholder Types
Shareholders
Proportion
Corporation
87.70%
Hedge Fund
3.49%
Investment Advisor/Hedge Fund
3.32%
Research Firm
1.54%
Investment Advisor
1.53%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Pension Fund
0.25%
Family Office
0.24%
Other
0.54%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
263
350.71M
99.08%
-19.09M
2025Q1
273
350.60M
99.12%
-19.40M
2024Q4
262
347.48M
98.58%
-23.77M
2024Q3
257
349.38M
99.14%
-19.72M
2024Q2
260
352.10M
99.92%
-21.43M
2024Q1
247
349.79M
99.91%
-25.18M
2023Q4
237
351.31M
100.35%
-21.66M
2023Q3
219
355.43M
101.52%
-16.80M
2023Q2
207
357.28M
102.06%
-12.23M
2023Q1
194
356.91M
101.97%
-11.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bausch Health Companies Inc
310.45M
87.77%
--
--
Mar 24, 2025
Icahn Associates Corporation
3.50M
0.99%
--
--
Mar 31, 2025
Deutsche Bank Securities Inc.
3.50M
0.99%
+3.50M
--
Mar 31, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
D. E. Shaw & Co., L.P.
1.88M
0.53%
-6.18K
-0.33%
Mar 31, 2025
GoldenTree Asset Management, LP
2.25M
0.64%
+516.07K
+29.79%
Mar 31, 2025
Whitebox Advisors, L.L.C.
1.62M
0.46%
+179.78K
+12.46%
Mar 31, 2025
Nomura Securities Co., Ltd.
1.26M
0.36%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
Invesco RAFI Developed Mkts ex-US SM ETF
0%
Schwab Fundamental International Small Equity ETF
0%
BNY Mellon US Small Cap Core Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
First Trust US Equity Opportunities ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Ballast Small/Mid Cap ETF
0%
Renaissance IPO ETF
0%
Invesco RAFI Developed Mkts ex-US SM ETF
Proportion0%
Schwab Fundamental International Small Equity ETF
Proportion0%
BNY Mellon US Small Cap Core Equity ETF
Proportion0%
Goldman Sachs MarketBeta US 1000 Equity ETF
Proportion0%
Invesco Zacks Mid-Cap ETF
Proportion0%
First Trust US Equity Opportunities ETF
Proportion0%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
Ballast Small/Mid Cap ETF
Proportion0%
Renaissance IPO ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
